United States Secures $330 Million in Latest Series B Funding Round

United States secured $330 million in its latest Series B, adding another data point to the Legal, Regulatory & Compliance funding market.

United States Raises $330 million in Funding

United States - Goodwin Advises Ollin Biosciences On Oversubscribed $330 Million Series B Financing. Established in 2023, Ollin Biosciences™ is a clinical-stage biopharmaceutical company dedicated to acquiring and developing best-in-disease therapies for vision-threatening diseases.

Investors Behind the Funding

The round was backed by new investor. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

United States operates in Legal, Regulatory & Compliance. United States's financing adds to recent private-market activity.

Strategic Use of Funds

Practice law with integrity, ingenuity, agility, and ambition.

Looking Ahead

said Jason Ehrlich, M.D., Ph.D., Co-founder and Chief Executive Officer of Ollin Biosciences.

Source reference: original announcement/article.